Neurology

Clario Enters into Definitive Agreement to Acquire WCG’s eCOA BusinessClario Enters into Definitive Agreement to Acquire WCG’s eCOA Business

Clario Enters into Definitive Agreement to Acquire WCG’s eCOA Business

Acquisition of WCG's electronic clinical outcome assessments (eCOA) business will expand Clario's scientific expertise and offerings in neuroscience PHILADELPHIA, March 10,…

3 months ago
Adaptive Sound Technologies, Inc. (ASTI) launches their gamma sound and light therapy device, the SOUND+THERAPY, on Walmart.com and Amazon.comAdaptive Sound Technologies, Inc. (ASTI) launches their gamma sound and light therapy device, the SOUND+THERAPY, on Walmart.com and Amazon.com

Adaptive Sound Technologies, Inc. (ASTI) launches their gamma sound and light therapy device, the SOUND+THERAPY, on Walmart.com and Amazon.com

SOUND+THERAPY is a bedside device that uses 40 Hertz gamma sound beats and light flashes to promote better sleep. Studies…

3 months ago
MedRhythms Announces FDA Class II Listing for Movive™ to Support Gait Rehabilitation and Motor Function for Parkinson’s DiseaseMedRhythms Announces FDA Class II Listing for Movive™ to Support Gait Rehabilitation and Motor Function for Parkinson’s Disease

MedRhythms Announces FDA Class II Listing for Movive™ to Support Gait Rehabilitation and Motor Function for Parkinson’s Disease

PORTLAND, Maine, March 6, 2025 /PRNewswire/ -- MedRhythms today announced that MR-005, the company's neurorehabilitation system to support gait rehabilitation…

3 months ago
Linus Health Achieves Landmark Research Recognition Across Peer-Reviewed Medical and Scientific JournalsLinus Health Achieves Landmark Research Recognition Across Peer-Reviewed Medical and Scientific Journals

Linus Health Achieves Landmark Research Recognition Across Peer-Reviewed Medical and Scientific Journals

Research validates the efficacy and accuracy of its digital solutions designed to detect early indicators of cognitive impairment BOSTON, March…

3 months ago
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated MilestonesAnnexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting…

3 months ago
Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular SurgeryStereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…

3 months ago
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 GuidanceANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8%Total Rare Disease quarterly net revenue of $87.0…

3 months ago
Orchard Therapeutics Announces Reimbursement Agreement in SpainOrchard Therapeutics Announces Reimbursement Agreement in Spain

Orchard Therapeutics Announces Reimbursement Agreement in Spain

LONDON, MADRID, and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) --  Orchard Therapeutics, a Kyowa Kirin company, announced it has recently…

3 months ago
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in TaiwanNxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as…

3 months ago
Ubie and Nucleus Genomics Partner to Enhance Access to Genetic Testing and Drive Early Screening for Improved Health OutcomesUbie and Nucleus Genomics Partner to Enhance Access to Genetic Testing and Drive Early Screening for Improved Health Outcomes

Ubie and Nucleus Genomics Partner to Enhance Access to Genetic Testing and Drive Early Screening for Improved Health Outcomes

Genetic testing can be critical to ensuring the early diagnosis and proper treatment of serious disease for patients of all…

3 months ago